In addition, targeting GFPT1 by DON blocked the PCK1-loss induced O-GlcNAclyation and liver cancer aggressiveness (Xiang et al., 2021), and enhanced anti-PD-1 immunotherapy effects in pancreatic cancer (Sharma et al., 2020). This evidence concerns the gene PCK1 and liver cancer.